Compare ARK Innovation ETF (ARKK) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Innovation ETF vs Eli Lilly And Co — how do they compare? ARK Innovation ETF trades at $81.6, while Eli Lilly And Co trades at $1,208.07 (market cap $1.08T). The key difference: Eli Lilly And Co pays a 0.57% dividend while ARK Innovation ETF pays none. Which is the better fit depends on your goals.
| ARKK | LLY | |
|---|---|---|
52-Week High | $92.50 | $1.24K |
52-Week Low | $63.52 | $639.43 |
Market Cap | — | $1.08T |
Sector | — | Health |
Enterprise Value | — | $1.13T |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Innovation ETF
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
